The Geoffrey Beene Foundation Alzheimer’s Initiative has announced its second online innovation challenge, which seeks to identify differences in early cognitive decline between genders. Winning submissions will share $100,000 in prize awards.
This new initiative — called the 2013 Geoffrey Beene Global NeuroDiscovery Challenge — was announced Monday at the Society for Women’s Health Research Gala in Washington, DC.
“Not unlike cancer, the Geoffrey Beene Foundation’s lead philanthropic cause, most researchers agree that the greatest potential to stop Alzheimer’s lies in the earliest stages of the disease, which is why we fund translational research. Innovative Challenges help to support that mission,” said Tom Hutton, trustee and CEO of the Geoffrey Beene Foundation and president and CEO of Geoffrey Beene, LLC. “We must redefine the solutions process and free the greatest minds of our time to do the work to help save and improve lives.”
Geoffrey Beene also sponsors the Builders of Science Award, one of Research!America’s annual Advocacy Awards.
Written proposals must be submitted by August 31. The responses will be judged by a stellar panel of experts, including Marietta Anthony, PhD, former director of women’s health programs at the Critical Path Institute; Howard Fillit, MD, of the Alzheimer’s Drug Discovery Foundation; Florence Haseltine, MD, PhD, founder of the Society for Women’s Health Research; Freda Lewis-Hall, MD, of Pfizer Inc.; Peter Rabins, MD, MPH, of Johns Hopkins Medicine; Alan Russell, PhD, of Carnegie Mellon University; Scott Small, MD, of Columbia University; and Kate Zhong, MD, of the Cleveland Clinic.
As many as five finalists will receive awards of at least $10,000; one of the finalists will then be selected for a $50,000 grand prize to be announced in late fall. Winning entries are eligible for further development and possible implementation of the proposed research in collaboration with the Geoffrey Beene Foundation.
“Women are two times at risk for Alzheimer’s because we outlive men, but we know little about other possible male-female differences. It’s time to find out if what’s true in cardiovascular disease, with different diagnostics and treatment of men and women, is also true for Alzheimer’s disease,” said Meryl Comer, president and CEO of the Geoffrey Beene Foundation Alzheimer’s Initiative.